Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 2 | 6 |
| List of Tables | 6 | 1 |
| List of Figures | 7 | 1 |
| Introduction | 8 | 1 |
| Global Markets Direct Report Coverage | 8 | 1 |
| Bone Metastasis Overview | 9 | 1 |
| Therapeutics Development | 10 | 2 |
| Pipeline Products for Bone Metastasis Overview | 10 | 1 |
| Pipeline Products for Bone Metastasis Comparative Analysis | 11 | 1 |
| Bone Metastasis Therapeutics under Development by Companies | 12 | 1 |
| Bone Metastasis Therapeutics under Investigation by Universities/Institutes | 13 | 1 |
| Bone Metastasis Pipeline Products Glance | 14 | 3 |
| Late Stage Products | 14 | 1 |
| Clinical Stage Products | 15 | 1 |
| Early Stage Products | 16 | 1 |
| Bone Metastasis Products under Development by Companies | 17 | 1 |
| Bone Metastasis Products under Investigation by Universities/Institutes | 18 | 1 |
| Bone Metastasis Companies Involved in Therapeutics Development | 19 | 14 |
| Ablynx NV | 19 | 1 |
| Alethia Biotherapeutics Inc. | 20 | 1 |
| Amgen Inc. | 21 | 1 |
| Amura Holdings Limited | 22 | 1 |
| Bayer AG | 23 | 1 |
| BiologicsMD, Inc. | 24 | 1 |
| ChemoCentryx, Inc. | 25 | 1 |
| Deciphera Pharmaceuticals, LLC | 26 | 1 |
| Oncobiologics, Inc. | 27 | 1 |
| Oncodrone BV | 28 | 1 |
| Osteologix Holdings Plc. | 29 | 1 |
| R-Pharm | 30 | 1 |
| Taiho Pharmaceutical Co., Ltd. | 31 | 1 |
| Terpenoid Therapeutics Inc | 32 | 1 |
| Bone Metastasis Therapeutics Assessment | 33 | 9 |
| Assessment by Monotherapy Products | 33 | 1 |
| Assessment by Target | 34 | 2 |
| Assessment by Mechanism of Action | 36 | 2 |
| Assessment by Route of Administration | 38 | 2 |
| Assessment by Molecule Type | 40 | 2 |
| Drug Profiles | 42 | 46 |
| AB-25E9 Drug Profile | 42 | 1 |
| ADM-01 Drug Profile | 43 | 1 |
| ALX-0141 Drug Profile | 44 | 2 |
| AM-3701 Drug Profile | 46 | 1 |
| AMG-161 Drug Profile | 47 | 1 |
| BKM-1644 Drug Profile | 48 | 1 |
| BKM-1740 Drug Profile | 49 | 1 |
| BMD-3151 Drug Profile | 50 | 1 |
| CCX-354 Drug Profile | 51 | 2 |
| DCC-3014 Drug Profile | 53 | 1 |
| denosumab Drug Profile | 54 | 9 |
| denosumab biosimilar Drug Profile | 63 | 1 |
| Drugs to Inhibit CXCL5 for Bone Metastasis and Breast Cancer Drug Profile | 64 | 1 |
| LG-1980 Drug Profile | 65 | 1 |
| Monoclonal Antibodies to Inhibit SVEP1 for Bone Metastasis Drug Profile | 66 | 1 |
| NBS-101 Drug Profile | 67 | 1 |
| OCD-155 Drug Profile | 68 | 1 |
| radium Ra 223 dichloride Drug Profile | 69 | 9 |
| Recombinant Protein for Bone Metastasis and Non-Small Cell Lung Cancer Drug Profile | 78 | 1 |
| roneparstat Drug Profile | 79 | 1 |
| RPH-203 Drug Profile | 80 | 1 |
| RSF-102 Drug Profile | 81 | 1 |
| RSF-103 Drug Profile | 82 | 1 |
| Small Molecules to Inhibit cFMS Kinase for Immunology and Oncology Drug Profile | 83 | 1 |
| Small Molecules to Inhibit GGDPS for Bone Metastasis and Oncology Drug Profile | 84 | 1 |
| TAS-115 Drug Profile | 85 | 1 |
| TPH-9 Drug Profile | 86 | 1 |
| vicrostatin Drug Profile | 87 | 1 |
| Bone Metastasis Dormant Projects | 88 | 3 |
| Bone Metastasis Discontinued Products | 91 | 1 |
| Bone Metastasis Product Development Milestones | 92 | 14 |
| Featured News &Press Releases | 92 | 1 |
| May 18, 2016: Bayer to Showcase Latest Data on Xofigo (radium Ra 223 dichloride) at ASCO 2016 | 92 | 1 |
| Mar 29, 2016: Bayer Receives Approval for Xofigo in Japan | 93 | 1 |
| Feb 03, 2016: NICE issues full guidance for Xofigoq (radium-223 dichloride) | 94 | 1 |
| Sep 14, 2015: Bayer to Present Data On Radium-223 Dichloride at ECC2015 in Vienna | 95 | 1 |
| Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease | 96 | 1 |
| Oct 09, 2013: Medivir: Positive results from a phase I study with MIV-711 for the treatment of osteoarthritis and other bone related disorders | 97 | 1 |
| Oct 01, 2013: Goodwin Biotechnology Announces the Return of AB-25E9 Monoclonal Antibody Project from Alethia Biotherapeutics | 98 | 1 |
| Jul 17, 2013: The New England Journal of Medicine publishes results from the phase III ALSYMPCA study of Xofigo | 98 | 1 |
| Jun 20, 2013: Algeta Opens Commercial Production Facility For Xofigo Injection In Kjeller, Norway | 99 | 1 |
| May 30, 2013: Algeta Announces First Sale Of Xofigo In US | 100 | 1 |
| Feb 15, 2013: Algeta Presents Further Sub-analysis Of Phase III ALSYMPCA Study Of Radium-223 Dichloride At 2013 Genitourinary Cancers Symposium | 101 | 1 |
| Jan 14, 2013: US Nuclear Regulatory Commission Issues Licensing Decision For Radium-223 Dichloride | 102 | 1 |
| Sep 17, 2012: Bayer To Present Data On Alpharadin At ESMO 2012 Congress | 102 | 1 |
| Aug 21, 2012: Medivir Commences Phase Ib Trial Of MIV-711 For Treatment Of Skeletal Disorders | 103 | 1 |
| Jun 04, 2012: Bayer Reports Updated Data From Phase III Study Of Alpharadin For Treatment Of Prostate Cancer | 103 | 3 |
| Appendix | 106 | 2 |
| Methodology | 106 | 1 |
| Coverage | 106 | 1 |
| Secondary Research | 106 | 1 |
| Primary Research | 106 | 1 |
| Expert Panel Validation | 106 | 1 |
| Contact Us | 106 | 1 |
| Disclaimer | 107 | 1 |